A large number of genetic associations with cervical cancer have been reported in hypothesis-driven candidate gene studies, but most studies have not included an independent replication or the results have been inconsistent between studies. In order to independently validate these associations, we reexamined 58 candidate gene/regions previously reported to be associated with cervical cancer using the gene-based Adaptive Rank Truncated Product test in a genome-wide association study ( After correction for multiple testing, only TNF remained statistically significant (P = 0.028). Two single-nucleotide polymorphisms that are in nearly perfect linkage disequilibrium (rs2857602 and rs2844484) contributed most to the association with TNF. However, they are not independent from the previously reported associations within the MHC region. The very low number of previously reported associations with cervical cancer that replicate in the Swedish population underscore the need to apply more stringent criteria when reporting associations, including the prerequisite of replicating the association as part of the original study.
Introduction
Cervical intraepithelial neoplasia and cervical cancer are caused by persistent infection with oncogenic forms of human papillomavirus (HPV) (1) . HPV infection is regarded as a necessary but not sufficient cause of cervical cancer. Although the majority of HPV infections resolve spontaneously, a small number of women carry a persistent HPV infection and are at high risk of developing cervical cancer (2, 3) . Technical and financial limitations have in the past restricted studies to a limited number of genetic markers in candidate genes selected on the basis of their proposed function. Classic human leukocyte antigen (HLA) alleles in the HLA class II genes HLA-DQA1, DQB1 and DRB1 (4, 5) and the class I gene HLA-B (6,7) have been found to be associated with cervical cancer in multiple studies. In addition, a large number of studies have reported cervical cancer to be associated with non-HLA loci involved in the immune response, DNA repair, cellular cycle and apoptosis induction (8, 9) , such as methylenetetrahydrofolate reductase (NAD(P)H; MTHFR), glutathione S-transferase mu 1 (GSTM1), microRNA 146a (MIR146A), tumor necrosis factor (TNF), cyclin-dependent kinase inhibitor 1A (CDKN1A), cyclin D1 (CCND1), interferon gamma (IFNG), cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1), tumor protein p53 (TP53) and x-ray repair complementing defective repair in Chinese hamster cells 1 (XRCC1). However, the hypothesisdriven candidate gene approach is subject to a number of potential biases and the results of many of these studies have been inconsistent or confusing (10) . For example, a meta-analysis of 49 studies showed no association of the polymorphism at codon 72 of the TP53 gene (Pro72Arg) with cervical cancer when the analysis was restricted to methodologically sound studies (11) . Unfortunately, meta-studies are an exception and most associations have been reported without replication.
The use of array-based genotyping technologies has made it possible to examine hundreds of thousands of single-nucleotide polymorphisms (SNPs) with a genome-wide distribution. Genome-wide association studies (GWASs) allow for a more unbiased examination of the association of common variants with cervical cancer. We recently performed the first genome-wide association study (GWAS) of cervical cancer in the patients and controls from Swedish population and confirmed previously known associations with classical HLA alleles, including HLA-B*0702, -DRB1*1301, -DRB1*1501, -DQA1*0103, -DQB1*0603 and -DQB1*0602 (12) . In addition, we identified three novel loci in the major histocompatibility complex (MHC) region, acting independently of the classic HLA alleles previously identified. The first locus is located between HLA-DRB1 and HLA-DQA1 (rs9272143), the second is adjacent to the MHC class I polypeptide-related sequence A gene (MICA; rs2516448) and the third at HLA-DPB2 (rs3117027). We also replicated the effect of these three loci in an independent case-control series (12) . rs2516448 was found to be in perfect linkage disequilibrium (LD; D′ = 1, r 2 = 1) with a deletion-insertion polymorphism (rs67841474), where the guanine (G) insertion causes a frameshift mutation (known as A5.1) in exon 5 of MICA, and this in turn results in a truncated MICA protein lacking part of the transmembrane domain and the whole cytoplasmic tail (12) . Association between variation in MICA and cervical cancer has also been reported previously, but the nature of this association has been unknown (13) . Recently, a cervical cancer GWAS in a Chinese population was performed and also found the strongest signals in the MHC region. Associations were found between HLA-DPB1 and HLA-DPB2 (rs4282438) and between ring finger protein 1 (RING1) and vacuolar protein sorting 52 homolog (VPS52; rs9277952). Associations were also reported with exocyst complex component 1 (EXOC1) at 4q12 (rs13117307) and gasdermin B (GSDMB) at 17q12 (rs8067378) (14) .
However, except for the HLA genes and MICA, the associations identified in previous hypothesis-driven studies with cervical cancer were not replicated at the genome-wide significance level used in the GWAS. A major reason for this is likely to be the very stringent threshold for significance used in GWAS, resulting in that causal genes with moderate genetic effects may be missed.
The purpose of this study was to perform a systematic examination of previously proposed candidate genes associated with cervical cancer using GWAS data from the Swedish population. We used the gene-based Adaptive Rank Truncated Product (ARTP) test to determine whether the set of candidate genes were enriched for lower P values than expected by chance. This gene-based association analysis relies on access to a representative set of SNPs in each gene rather than being based on a single SNP, and increases the probability of identifying genetic variants that individually have a modest effect at the gene level.
Abbreviations: HPV, human papillomavirus; GWAS, genome-wide association study; SNP, single-nucleotide polymorphism; MHC, major histocompatibility complex; MICA, MHC class I polypeptide-related sequence A gene; HLA, human leukocyte antigen; LD, linkage disequilibrium; PCA, principal components analysis; ARTP, Adaptive Rank Truncated Product; TNF, tumor necrosis factor; TSBH, two-stage Benjamin and Hochberg.
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Material and methods
Population and genotype data
Subjects included in this study were from a GWAS of cervical cancer in a Swedish population, with the SNP data generated on the Illumina Human OmniExpress BeadChip (Illumina, San Diego, CA; 731 422 SNPs). Informed consent was obtained from all subjects and the study was approved by the regional ethics review board in Uppsala (Dnr 2005:185) . The details of the material and quality control have been described elsewhere (12) . Briefly, after stringent quality control, data from 1034 cervical cancer patients and 3948 controls were available for 632 668 SNPs with an overall call rate of 99.92%. Population stratification was investigated by principal components analysis (PCA) undertaken with the EIGENSTRAT package (15) . Nine statistically significant principal components were identified based on the Tracy-Widom statistic (P < 0.05) from the PCA. However, none of them are significantly associated with case-control status (all P > 0.05), suggesting the population substructure cannot confound the association results. The genomic inflation factor (λ) on single-maker association analysis for this data set was 1.03. Power analysis was performed for this study using QUANTO (http://biostats. usc.edu/Quanto.html) based on the cervical cancer incidence rate of 4.7 × 10 
Candidate genes examined
Candidate genes were identified based on publications that appeared between 1 January 2012 and 31 March 2013, using PubMed and the keywords 'Cervical Cancer' and 'Association'. All papers (including meta-analyses) were manually reviewed for relevance. We excluded papers presenting no association and those focusing only on HLA Class I and II genes (HLA-A, -B, -C, -DPA1, -DPB1, -DQA1, -DQB1, -DRA, and -DRB1) and MICA because their effects were replicated in the GWAS of cervical cancer in the Swedish population. We did not discriminate between different forms (stages) of cervical cancer (cancer in situ and invasive cervical cancer). Only studies published in peer-reviewed and English-language journals were considered. This identified 42 genes and we further added 23 candidate genes, including Fc fragment of IgG, low affinity IIIa, receptor (CD16a; FCGR3A), interleukin 1, alpha (IL1A), CD28 antigen (CD28), polymerase (DNA directed) nu (POLN), secreted phosphoprotein 1 (SPP1), toll-like receptor 2 (TLR2), CLPTM1-like (CLPTM1L), CD83 molecule (CD83), general transcription factor IIH, polypeptide 4 (GTF2H4), sulfatase 1 (SULF1), lysosomal protein transmembrane 4 beta (LAPTM4B), interferon gamma (IFNG), 2′-5′-oligoadenylate synthetase 1 (OAS1), 2′-5′-oligoadenylate synthetase 2 (OAS2), deoxyuridine triphosphatase (DUT), fanconi anemia, complementation group A (FANCA), signal transducer and activator of transcription 3 (STAT3), transmembrane channel-like 8 (TMC8), interferon regulatory factor 3 (IRF3), microRNA 499a (MIR499A), macrophage migration inhibitory factor (MIF) and DNA meiotic recombinase 1 (DMC1), that have been reported in earlier association studies . All genes included in this study and the references for them are listed in Supplementary Table S1, available at Carcinogenesis Online.
The genomic coordinates for the start-and endpoint of candidate genes (all transcripts combined) were collected from NCBI's Reference Sequence Database, as implemented in the University of California Santa Cruz genome browser (hg19 assembly). All SNPs from our previous GWAS study located within 10 kb upstream/downstream of a candidate gene were included in the gene-based association analysis. Five pairs of genes (GDF2-GDF10, PRDX3-GRK5, C1RL-CLSTN3, OAS3-OAS2 and TMC6-TMC8) were merged into five larger regions, respectively, as they had overlapping intervals or very close to each other (distance < 21 kb between two genes). If a reported associated SNP was missing in our data set, the online SNP Annotation and Proxy Search (16) tool was used to search for proxy-SNPs (SNP with r 2 ≥ 0.8).
Gene-based association analysis
The association between each SNP and cervical cancer risk was estimated using unconditional logistic regression assuming a log-additive genetic model in PLINK (17) . Adjustment for population stratification was performed by including the nine informative principal components derived from PCA as covariates in the logistic regression. The gene-level association, which combines the SNP association pattern for each gene, was calculated using the ARTP test (18) , as implemented in the ARTP R-package (v2.0.2; Division of Cancer Epidemiology and Genetics, National Cancer Institute; http://dceg.cancer.gov/ tools/analysis/artp). In our analysis, the phenotype was randomized for 4000 times while preserving the original case-control ratio. Default values for all other parameters were used. Multiple testing was corrected using the two-stage Benjamin and Hochberg (TSBH) step-up false discovery rate procedure (alpha set to 0.05) (19) , as implemented in the Multtest R-package (v2.14.0) (http:// www.bioconductor.org/packages/release/bioc/html/multtest.html).
Results
The candidate gene list generated through the PubMed search resulted in 60 papers with 44 polymorphisms in 42 genes that have been reported to be associated with cervical cancer. In five of these genes [DEAD (Asp-Glu-Ala-Asp) box helicase 1 (DDX1), immunoglobulin-like domain containing receptor 1 (ILDR1), growth differentiation factor 2 (GDF2), growth differentiation factor 10 (GDF10) and mediator complex subunit 24 (MED24)], tag SNPs were used in a gene-based analysis (20) , but information of which SNPs the analysis was based was not available. We also added 14 papers published between 2004 and 2011 with an additional 35 polymorphisms in 23 other genes reported to be associated with cervical cancer (including an additional six variants in two of the genes already included in the literature search). In total, 79 polymorphisms in 65 genes were included in further analysis (Supplementary Table S1 , available at Carcinogenesis Online). All SNPs in the Swedish GWAS data set located within 10 kb from the start-and endpoint of each of the 65 selected gene/regions were included in the gene-based analysis. Five pairs of genes (GDF2-GDF10, PRDX3-GRK5, C1RL-CLSTN3, OAS3-OAS2 and TMC6-TMC8) were merged into five larger regions, respectively, as they had overlapping intervals or very close to each other (distance < 21 kb between two genes). Two genes were excluded from the analysis as there was no SNP on the Illumina Human OmniExpress BeadChip in that gene (FCGR3A), or the association was due to a null allele represented by a deletion including the whole gene [glutathione S-transferase theta 1 (GSTT1)] (21). Thus, the final gene-based analysis was based on 1143 SNPs in 58 genes/regions (Table I ). The median size of a gene interval was 63 307 bp (range: 20 099-307 917 bp), the median number of SNPs per gene/region was 20 (range: 4-117) and the average distance between SNPs in each gene was 4417 bp (range: 551-25 949 bp). Adjustment for the nine informative principal components derived from PCA indicated that population stratification was unlikely to account for the association of each tested SNP (Supplementary Table S2 , available at Carcinogenesis Online).
In 78% (45/58) of the genes/regions, the SNP array used in our GWAS (Illumina Human OmniExpress BeadChip) contained at least one same SNP as was reported in the original paper describing the association, or a SNP that could act as a proxy (r 2 ≥ 0.8). The P values of candidate gene polymorphisms and proxy SNPs in our GWAS data are shown in Supplementary Table S1, available at Carcinogenesis Online. Five individual SNPs had nominal P values ≤ 0.05 [rs380286 in CLPTM1-like (CLPTM1L), P = 0.021; rs1800629 in TNF, P = 0.042; rs10518696 in RAD51 recombinase (RAD51), P = 0.038; rs11575934 in interleukin 12 receptor, beta 1 (IL12RB1), P = 0.045 and rs11615 in excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1), P = 0.016], but none of these associations remained significant after correction for multiple testing.
The gene-level analysis showed that 8 of the 58 gene/regions had a nominal P value < 0.05 (TNF: 32 SNPs, P = 5.0 × 10 −4 ; DEAD (Asp-Glu-Ala-Asp) box helicase 1 (DDX1): 13 SNPs, P = 2.2 × 10 −3 ; exonuclease 1 (EXO1): 24 SNPs, P = 4.7 × 10 −3 ; ERCC1: 10 SNPs, P = 0.020; transmembrane channel-like 6 and 8 genes (TMC6 and TMC8): 18 SNPs, P = 0.023; SPP1: 11 SNPs, P = 0.028; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2): 10 SNPs, P = 0.033 and chloride channel, voltage-sensitive 7 (CLCN7): 23 SNPs, P = 0.047; Table I ]. After correcting for multiple testing, only TNF remained significant (TSBH P = 0.028) and DDX1 had a borderline significant association (TSBH P = 0.064).
Of the 32 SNPs located in the TNF gene, 12 (38%) had nominal P values < 0.05. One of the three previously reported polymorphisms in TNF (rs1800629) was included in our study (see Supplementary  Table S1 , available at Carcinogenesis Online) and had a nominal P value = 0.042. Among the SNPs that contributed most to the genebased association were two (rs2857602, P = 1.2 × 10 −6 and rs2844484, P = 1.1 × 10 −6 , respectively; Table II), which are in nearly perfect LD with each other (r 2 = 0.996), but in low LD with rs1800629 (r 2 ≤ 0.12).
These two SNPs are located 10.2 kb and 7.4 kb upstream of the TNF transcription start site, respectively, but only 6.7 kb and 3.9 kb from the transcription start site of the lymphotoxin alpha (LTA) gene (also known as TNFβ). TNF is located in the MHC region, as are the three top hits identified in our previous GWAS (rs9272143 between HLA-DRB1 and HLA-DQA1, rs2516448 adjacent to MICA and rs3117027 Five pairs of genes (GDF2-GDF10, PRDX3-GRK5, C1RL-CLSTN3, OAS3-OAS2 and TMC6-TMC8) were merged into five larger regions, respectively, as they had overlapping intervals or very close to each other.
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in HLA-DPB2). As the MHC region includes long stretches with extended LD (23), we performed a conditional analysis for these markers. Upon conditioning on both rs9272143 and rs2516448, no statistically significant association was observed with the TNF SNPs rs2857602 or rs2844484 [odds ratio = 1.08, 95% confidence interval = 0.97-1.20, P = 0.170 for both SNPs; Table II ], suggesting that the association with rs2857602 and rs2844484 is driven by the joint effects of both rs9272143 and rs2516448. A second gene, DDX1, had a borderline significant association after correction for multiple testing (TSBH P = 0.064). Among the 13 SNPs included in our gene-based test, four SNPs (rs3755132, rs3755133, rs976016 and rs4668951) in high LD with each other (r 2 ≥ 0.93) and located both upstream and downstream of the gene have nominal P values < 6.0 × 10 −4 .
Discussion
We have recently performed a GWAS of cervical cancer in the Swedish population and identified three susceptibility loci in the MHC region, in addition to known associations with classic human HLA alleles (12) . Except for the HLA genes and MICA, none of the candidate genes that have been identified in previous hypothesis-driven association studies were identified in our GWAS, using single-SNP analysis. Hypothesisdriven candidate gene studies have been a major approach to study the molecular etiology of cervical cancer. In this study, we employed a genebased analysis to search for enrichment of low P values in previously proposed candidate genes for cervical cancer susceptibility using GWAS data. The ARTP test uses phenotype permutation to correct naturally for biases introduced by LD and gene size. It keeps all the information constant and only permutes the case-control status among individuals. The same individuals are used, maintaining the same LD structure. This minimizes false positive associations arising from LD because, even if LD was leading to an excess of significance for a gene, this LD block would be identical across all data sets using randomized phenotypes. The same is true for gene size because a larger gene has more potential SNP sites and therefore more potential false positives, but this bias will be the same for the original and the simulated data sets. The gene-based association analysis showed that 8 of the 58 genes/ regions tested had a nominal P value < 0.05, but only TNF remained statistically significant after correcting for multiple testing (TSBH P = 0.028; Table I ). As shown in the conditional analysis, the association with TNF seems to be driven by both rs9272143 and rs2516448 and may therefore be secondary to the association with MICA and the variation between HLA-DRB1 and HLA-DQA1. Thus, our attempt to replicate the effect of loci previously postulated to be associated with cervical cancer did not provide support for the independent effect of any of the 58 candidates.
The lack of success in replicating the effect of candidate gene studies can be attributed to a number of factors, including differences in genotyping methods, differences in the genetic background between the discovery population and that used for replication (ethnicity), differences in the tumor stages, difference in biological effect between cohorts due to modification of environmental factors, lack of statistical power in the replication study (false negative results) or type I error (false positives in the initial study). However, although the typing technology itself has evolved over the time span of the studies included, we consider this factor less likely to account for the lack of replication because many of the studies were performed in the last few years. One important confounder is probably the different ethnic backgrounds between the discovery and replication populations because the majority of the original candidate gene studies included were performed in Asian populations while we used data for replication from a Caucasian (Swedish) population. However, our focus on all SNPs within a gene/region rather than on specific SNPs identified from previous studies guards against this possibility. A GWAS for cervical cancer was recently published in the Chinese population and this would make it possible to address the impact of ethnic origin on the replication success. The clinical endpoint also varied between studies, from persistent versus transient infection, cervical cancer in situ and invasive cancer, and the results may therefore show some heterogeneity. However, the majority of studies either used cervical cancer in situ or invasive cancer as outcome. Although the cervical cancer GWAS data used for replication is the largest and most comprehensive in Caucasian populations published to date, even higher power may be needed to detect small genetic effects in a complex disease. As shown in Supplementary Table S3 , available at Carcinogenesis Online, the power of our study is <80% to detect the associated variants with effect size (odds ratio) ≤ 1.2 and minor allele frequency ≤ 0.15 and those with effect size ≤ 1.3 and minor allele frequency ≤ 0.05. In addition, as shown in Supplementary First, the sample size of many of the original candidate gene studies is small, and these do not have the power to detect the moderate effects of loci involved in a complex human disease. Second, the hypothesisdriven candidate gene studies generally had poor coverage of common Odds ratios and 95% confidence intervals for minor allele were derived from logistic regression assuming log-additive model with adjustment for the nine significant principal components generated by PCA. genetic variants. With the resources provided by the HapMap and 1000 Genomes Project, coupled with decreases in genotyping costs, future genotyping should cover the majority of common and rare variation present in the samples. Third, as many as 61% of the candidate genes have only been examined in one material, which makes it impossible to elucidate the level of false positives or false negatives finding. Given the small effect size of most genetic variants involved in complex diseases and the distorting potential of a publication bias in favor of positive associations, a single positive finding cannot be viewed as sufficient evidence. The low statistical power and non-uniform SNP coverage both contribute to false negatives (i.e. true susceptibility loci with nonsignificant candidate gene findings). For example, the association in our GWAS and the independent replication provided firm evidence for the frameshift mutation A5.1 of MICA as a risk factor for cervical cancer. However, the association of MICA with cervical intraepithelial neoplasia and cervical cancer had been addressed in two earlier smaller studies of the Swedish population, both with negative results (24, 25) which led to the exclusion of MICA from further consideration.
We are therefore left with the observation that the majority of genetic risk factors for cervical cancer do not replicate across studies. This is not without precedence because meta-studies conducted on candidate genes associated with cervical cancer have been unable to establish an effect of the associations studied (11) . However, one finding in the literature that has been very consistent is the association between MICA and HLA genes within the MHC region and cervical cancer. The fact that MHC results have been consistent while other candidate regions have not highlights the importance of targeting the MHC region in future studies of the genetics of cervical cancer. Furthermore, in order to further our understanding of the genetic susceptibility to cervical cancer, it is imperative that association studies, whether based on a hypothesis-free or candidate gene design, include a replication in an independent case-control cohort from the same population and a characterization of the biological function for candidate genes and SNPs. This increases the research effort but is necessary for a better understanding of the importance of genetic factors in the susceptibility and development of cervical cancer.
Supplementary material
Supplementary Table S1-S3 can be found at http://carcin.oxfordjournals.org/.
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